Introduction
Graves’ disease
PATHOGENESIS
Edited by: Salman Razvi, Newcastle University, United KingdomReviewed by: Ilaria Muller, University of Milan, Italy; Danian Chen, Sichuan University, China†ORCID: Magdy Mohamed Allam, Azathioprine (AZA) interferes with the activation of T and B lymphocytes, which are the main cells involved in the pathogenesis of Graves’ disease (GD). The aim of this study was to investigate the effectiveness of AZA as an adjuvant therapy to antithyroid drugs (ATDs) for moderate and severe GD. In addition, we conducted an incremental cost-effectiveness analysis of AZA to determine its cost-effectiveness.